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Summary 
Background 
Lyme disease is the result of an infection, caused by the Borrelia burgdorferi bacterium, 
which is common in ticks; people can develop Lyme disease after being bitten by an 
infected tick. This report describes one of a series of evidence reviews on Lyme disease 
commissioned by the Department of Health (England) Policy Research Programme and 
undertaken by the Department of Health Reviews Facility. This evidence review focuses on 
treatment for Lyme disease. Its aim is to bring together evidence from patients, clinicians 
and researchers about their experiences of receiving, delivering or evaluating 
interventions for Lyme disease in order to identify factors that might impact on successful 
treatment.  
Review questions and methods 
The review aimed to address the following questions:- 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
treatments for Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
treatments at different stages of Lyme disease?  
Before starting work on the evidence reviews we produced a systematic map which 
covered the whole range of research evidence on Lyme disease in humans (Stokes et al., 
2017). We searched 17 electronic databases and conducted additional web-based 
searching for unpublished and grey literature. We included empirical research published 
from 2002 on Lyme disease in humans. Studies were coded in relation to their topic focus 
and characteristics.  
For this in-depth review focusing on treatment, studies had to report patient or clinician 
views or experiences relating to the treatment of Lyme disease or, in order to gather 
researcher’s insights, an evaluation of a Lyme treatment intervention. Studies could use a 
qualitative or quantitative design. Following assessment of the evidence to answer these 
questions we sought feedback on the findings from eight UK patient advocacy groups. 
Findings 
We found insufficient evidence from patient and clinician studies to undertake a 
meaningful synthesis on treatment experiences. Whilst a few studies had a partial focus on 
experiences, the evidence overall is extremely limited. One qualitative and one 
quantitative study provided some evidence on patient experiences of treatment and five 
quantitative studies on clinician experiences. Researcher insights from evaluation studies 
were deemed to be too insubstantial to be informative. Patient advocacy groups lamented 
the lack of evidence on treatment experiences for this review, and the lack of evidence on 
treatment for Lyme disease in general. 
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Conclusions 
Insufficient evidence was available to produce a useful or meaningful synthesis on 
experiences of treatments for Lyme disease. Research is urgently needed to fill this gap as 
patient and clinician experiences are important for understanding ‘real world’ factors that 
might impact on the implementation of effective treatment.   
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1 Background 
This report is one of a series on Lyme disease commissioned by the Department of Health 
(England) (DH) Policy Research Programme and undertaken by the Department of Health 
Reviews Facility.  
The overarching project consists of a comprehensive evidence map on Lyme disease in 
humans and four systematic reviews on:- 
1) the incidence and surveillance of Lyme disease 
2) patient, clinician and researcher experiences of diagnosis of Lyme disease 
3) patient, clinician and researcher experiences of treatment and management of 
Lyme disease 
4) prevention of Lyme disease 
This report contains the findings from review 3) where the objective was to examine 
evidence from patients, clinicians and researchers about their experiences of receiving, 
delivering or evaluating treatments for Lyme disease. The aim is to use this research 
evidence to assist in the interpretation and implementation of evidence about the efficacy 
and safety of different treatments for Lyme disease patients. 
1.1 Lyme disease 
Lyme disease is the result of an infection, caused by the Borrelia burgdorferi1 bacterium, 
which is common in ticks; people can develop Lyme disease after being bitten by an 
infected tick (Public Health England, 2016).  
In many cases, an early sign of the infection is an erythema-migrans or ‘bulls-eye’ rash 
(Stanek and Strle, 2003, Wormser et al., 2006). Clinical complications resulting from Lyme 
disease include joint, nervous system, and heart problems (Stanek et al., 2011, Stanek et 
al., 2012, Wormser et al., 2006). Some evidence suggests that presentation is not always 
typical (Bingham et al., 1995, Christen et al., 1993) and that complications may be more 
wide-ranging and persistent. However, uncertainties around persistent infection mean 
that the notion of chronic Lyme or post-treatment Lyme disease (PTLD) is contested and 
has been the subject of ‘substantial and polarizing debate’ in the field of medicine for 
many years (Rebman et al., 2017).   
 
1.2 Treatment for Lyme disease 
Treatment with antibiotics is the standard care approach for people with Lyme disease. In 
the UK a two-week course of oral antibiotics (Doxycycline, amoxicillin or cefuroxime) is 
recommended for patients with a typical acute presentation of Lyme involving an 
erythema-migrans rash. Longer courses of antibiotics, or intravenous administration, may 
                                            
1 We refer here to ‘Borrelia Burgdoferi Sensu Lato’ which includes all sub-species (including afzelii, 
garinii, mayonii, bissettii, lusitaniae and spielmanii). We have used the abbreviated phrase in the 
text for improved accessibility. 
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be considered for those with neurological or arthritic complications 
(https://www.gov.uk/government/publications/lyme-disease-diagnosis-and-
treatment/lyme-disease-diagnosis-and-treatment). As the existence of chronic Lyme 
disease is contested, efforts to treat those with longer term or wide-ranging symptoms is 
controversial (Berende et al., 2016).   
1.3 Using experiential evidence to help interpret and implement evidence of 
effectiveness and safety 
Systematic reviews of randomized controlled trials (RCTs) are considered the ‘gold 
standard’ for assessing the effectiveness and safety of medical treatments (Sullivan, 
2011). However, as the strength of an RCT for evaluating treatment effectiveness comes 
from adopting carefully controlled experimental conditions, other research is needed to 
translate and interpret that evidence for real-world situations. For example, patients 
often have characteristics and experiences that differ from the strict inclusion criteria 
that apply to those participating in RCTs, and therefore the information gained from an 
RCT may be less applicable to a broader group of patients (Sullivan, 2011).  
Bringing together evidence from patients and clinicians about their experiences of 
receiving and delivering treatment can highlight issues that impact on the effectiveness of 
treatments in real-world settings. For example, qualitative evidence syntheses have 
identified patient factors leading to discontinuation of treatment (Rashid et al., 2014), 
clinician factors which hinder appropriate prescribing (Cullinan et al., 2015) and clinician 
and parent views about prescribing antibiotics for children (Lucas et al., 2015).  
1.4 Previous research on the treatment and management of Lyme disease 
In 2012 a priority setting exercise on Lyme disease was conducted in the UK by The James 
Lind Alliance, an NGO which involves patients, carers and medical professionals in 
identifying priorities for future research. Of the ten research priorities identified, seven 
focused on the efficacy and consequences of treatments for Lyme disease at different 
stages (JLA, 2012). Recent systematic reviews have examined evidence on the efficacy 
and safety of treatments for Lyme patients with neurological symptoms (Lyme 
neuroborreliosis) (Cadavid et al., 2016, Dersch et al., 2015). NICE is currently undertaking 
a series of evidence reviews on treatment efficacy in relation to a range of Lyme-related 
conditions to inform the development of a clinical guideline. 
However, to our knowledge, no previous systematic review has attempted to identify, 
assess and synthesise evidence of patients’ and clinicians’ experiences of treatment of 
Lyme disease.  
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2 Aims and methods 
This section provides a brief overview of the methods used to conduct the review. A 
detailed account of the methods is provided in Section 5. 
2.1 Aims 
The primary objective of this review is to bring together evidence from patients, clinicians 
and researchers about their experiences of receiving, delivering and evaluating treatments 
for Lyme disease. The aim of the work is to help to understand the issues that may help or 
hinder the prescription and use of effective treatments in real-world settings; in particular 
to help interpret evidence about the efficacy and safety of different treatments for Lyme 
disease patients. 
2.1.1 Review questions 
The review aimed to address the following overarching questions:- 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
treatment/management of Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
findings about effective treatment at different stages of Lyme disease? 
2.2 Methods 
2.2.1 Study identification 
The first phase of the project involved producing a systematic evidence map covering the 
whole range of research evidence on Lyme disease in humans published in or since 2002. 
We sought relevant studies from within the map for this systematic review.   
Full details of the systematic map are available elsewhere (Stokes et al., 2017). 
2.2.2 Inclusion criteria 
To be included in this evidence review, studies had to meet the following criteria:  
 A qualitative or quantitative study that reports patient views relating to the 
treatment of Lyme disease and which reports methods for data collection and 
analysis. 
 A qualitative or quantitative study that reports clinician views, experiences, 
knowledge or behaviours relating to the treatment or management of Lyme disease 
and which reports methods for data collection and analysis. 
 An evaluation of a Lyme disease treatment included in one or more of the NICE 
evidence reviews that includes informal researcher views about factors that help 
or hinder treatments in real world settings.  
2.2.3 Data extraction, quality appraisal and synthesis 
We planned to use thematic analysis (Thomas and Harden, 2008) to inductively code and 
analyse data from qualitative studies and to narratively synthesise evidence from surveys. 
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We planned to assess quality using pre-existing tools as appropriate for appraising 
qualitative evidence (Shepherd et al., 2010) or survey evidence (Wong et al., 2008). 
2.2.4 Quality assurance 
All studies considered for inclusion in the systematic review were screened independently 
by two reviewers using the full text.  
2.2.5 Consultation with patient advocacy groups 
In October 2017, we shared the key findings with eight UK-based patient advocacy groups 
via an online survey and each group was invited to comment.   
Prior to sharing findings, we conducted a series of face-to-face consultations with the 
advocacy groups in July 2017 for our review on experiences of diagnosing Lyme disease 
(Brunton et al. 2017). In these face-to-face consultations, we did not ask participants to 
comment on treatment issues directly, however several participants raised issues relating 
to treatment, which we summarise in this report. Comments relating to Lyme disease 
treatment from both consultation exercises are reported in section 3.1.5.
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3 Findings 
We found insufficient evidence from patient and clinician studies to undertake a 
meaningful synthesis on treatment experiences. Some studies we identified had a partial 
focus on treatment experiences but data were too limited in extent and relevance to 
warrant synthesising. Below we provide an overview of the evidence considered for 
inclusion, but excluded because of these limitations.  
3.1 Overview of available evidence on patient, clinician and researcher experiences 
of treatment for Lyme disease 
3.1.1 Evidence on patient experiences of treatment for Lyme disease 
Nineteen research studies identified from the evidence map focus on the views of patients 
with Lyme disease. However, seventeen of these did not focus on treatment experiences 
and two had only a partial focus.  
Both of these studies, conducted in the USA, provided very limited information: one study 
included qualitative data (Ali et al., 2014) and one quantitative data (Johnson et al., 
2014). From the qualitative study a theme emerged around the use of ‘Unconventional 
therapies to treat chronic Lyme Disease’. The authors described how some patients sought 
out providers who offered long-term antibiotic therapy or complementary and alternative 
therapies (Ali et al., 2014) (p. 5 of 8). The quantitative study reported the reasons why 
some participants were not currently taking antibiotics; for example because they were 
using other treatments, were currently well or in remission, or because of financial 
constraints (Johnson et al., 2014) (p.5 of 21). 
Thus whilst two patient views studies partially meet the criteria for inclusion, the 
limitations of the available data, in terms of a) the extent and/or b) the lack of depth or 
richness, precluded undertaking a meaningful synthesis of evidence on patient 
experiences. 
3.1.2 Evidence on clinician experiences of treating/managing Lyme disease 
Nine research studies identified from the evidence map focus on the knowledge, attitudes 
and behaviours of clinicians with regards to Lyme disease. Whilst five quantitative studies 
included some data relating to clinicians’ treatment practices none focused in-depth on 
treating or managing the condition. The limited data precluded meaningful synthesis.  
3.1.3 Evidence on researcher insights about treatment for Lyme disease 
We examined studies included in the 2017 NICE evidence reviews on efficacy of 
treatments for Lyme disease to explore whether researcher insights and or reflections 
reported in the introduction or discussion sections of the research reports would provide a 
useful lens through which to further understand experiences of treatment. However, this 
source of evidence was deemed too ‘thin’ to produce a useful synthesis. 
3.1.4 Other qualitative evidence on treatment for Lyme disease 
We identified one qualitative study which focuses specifically on treatment for Lyme 
disease but from the perspective of the general public rather than from patients, 
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clinicians or researchers (Macauda et al., 2011). This US-based study explored public 
perceptions about the need for long-term treatment of Lyme disease following persistent 
symptoms.  
3.1.5 Patient advocacy groups views on these findings 
When we asked patient advocacy groups, in October 2017, to comment on the key findings 
of this review, two of the eight groups provided feedback. Both indicated the need for 
future research to focus on patients’ and clinicians’ experiences of Lyme disease 
treatment.  
Similarly, during our face-to-face consultations with eight groups in July 2017, a number 
commented on, and lamented, the lack of evidence on treatment experiences for this 
review, and the lack of evidence on treatment for Lyme disease in general. One noted the 
predominance of evidence from the USA and its limited relevance to the UK because the 
strains of Borrelia commonly found in the UK are different to those found in the USA.   
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4 Discussion and conclusions 
4.1 Gaps and limitations in the evidence base on Lyme disease treatment 
4.1.1 Limited evidence on stakeholder experiences of treatment 
The initial aim of this review was to draw together evidence on the experiences and 
insights of patients, clinicians and researchers with regard to treatment for Lyme disease.  
By doing so, we hoped to aid understanding of factors which might impact on treatment 
effectiveness. However, due to limitations of the evidence this has not been possible. This 
is in contrast with stakeholder experiences of the diagnosis of Lyme disease (Brunton et 
al., 2017).  
4.2 Conclusions  
The current evidence base precludes drawing any conclusions about stakeholder views on 
treatment/management of Lyme disease. The implications below address future research 
needs only.  
4.2.1 Implications for future research 
Qualitative and quantitative research which focuses on patient and clinician experiences 
of treatments for Lyme disease is needed. Qualitative research, and in particular 
embedded qualitative process evaluations of effectiveness studies, would enable 
understanding of the issues and complexities faced by patients and clinicians around 
treatment for Lyme disease. Quantitative survey research would enable understanding of 
how widespread any issues and problems are and how they vary in different populations. 
As such, this research would provide insight into why interventions might or might not be 
effective for particular patient groups.  
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5 Detailed methods 
5.1.1 Review questions 
The review aimed to address the following overarching questions in relation to stakeholder 
experiences of Lyme disease treatment:- 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
treatment/management of Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
findings about treatment effectiveness at different stages of Lyme disease? 
5.1.2 User involvement 
We worked closely with the review commissioners throughout in order to ensure that the 
review is closely aligned with their needs and emerging programme. In particular we 
sought to identify research avenues that would support and complement the evidence 
being assembled by NICE in 2017 to produce a guideline for Lyme disease. 
We also convened a Scientific Advisory Group (AG) of UK and international academics and 
UK policy-makers to obtain specialist expertise and input. The AG provided advice on an 
as-needed basis with regard to technical issues relating to the research questions, 
concepts and definitions as well as strategies for dissemination and impact. Lastly, we ran 
a series of consultations with patient and practitioner groups to help interpret our 
emerging findings in relation to current UK experiences. 
5.1.3 Study identification 
As noted above, the first phase of the project involved producing a systematic evidence 
map covering the whole range of research evidence on Lyme disease in humans. We 
searched 17 electronic databases and conducted additional web-based searching for 
unpublished and grey literature. We included empirical research published in or since 2002 
on Lyme disease in humans. Studies were coded in relation to their topic focus and 
characteristics. The findings of the map coding were then used to identify studies for this 
review. Full details of the methods and findings of the systematic map are available in the 
map report (Stokes et al., 2017). 
5.1.4 Inclusion criteria 
To be included in this review studies from the systematic evidence map needed to meet 
the criteria set out in table 5.1.4 below.  
 
 
 
 
11 
Table 5.1.4: Criteria for inclusion in the in-depth review 
To be included in the evidence review on experiences of Lyme treatment studies 
needed to be either of the following:- 
 A qualitative or quantitative that reports a) research methods and b) 
findings about patient views relating to the treatment or care of Lyme 
disease. 
 A qualitative or quantitative study that reports a) research methods and b) 
findings on practitioner views, experiences, knowledge or behaviours 
relating to the treatment or care of Lyme disease. 
 An evaluation of a Lyme treatment intervention that is a) included in one 
or more of the NICE evidence syntheses relating to treatment and b) 
provides the authors’ informal views about factors which may enhance or 
hinder delivery of treatments in real world settings.  
5.1.5 Data extraction and quality appraisal 
Since no studies met the inclusion criteria for this evidence review quality appraisal and 
data extraction were not undertaken.  
However, we had planned to employ an inductive approach for extracting and coding 
qualitative data using line-by-line coding. For quality appraisal we planned to assess any 
included qualitative patient and clinician studies using a modified set of criteria that were 
developed for examining the findings of evaluations of intervention processes in a review 
of behavioural interventions for sexually transmitted diseases in young people (Shepherd 
et al., 2010). The criteria were based on previous work at the EPPI-Centre on assessing the 
quality of qualitative research and process evaluations (Harden, 2007b, Harden, 2007a) 
and the work of others in the field (Popay et al., 2003). For included quantitative data we 
planned to use the quality assessment tool for systematic reviews of observational studies 
(QATSO) (Wong et al., 2008). 
5.1.6 Synthesis methods 
We planned to use thematic analysis (Thomas and Harden, 2008) to inductively analyse 
data from the studies. In this method initial descriptive themes are organised into higher-
order analytical themes that move ‘beyond’ the original findings of the studies in order to 
directly address the review questions. 
5.1.7 Quality assurance 
Screening of full-text of studies of patient views and practitioner experiences was 
undertaken by two reviewers working independently with differences resolved by 
discussion. For assessment of the researcher insights from treatment evaluations, a single 
reviewer conducted initial assessments which were then verified by a second reviewer. 
5.1.8 Consultation on key findings with patient advocacy groups 
In October 2017, following the completion of our analyses, we shared the key findings with 
eight patient groups. The findings were presented as a series of bullet points via an online 
survey and stakeholder groups were invited to comment. We requested that each group 
provide a single collated response for their group. As one group was unable to meet this 
request we had a member of the research team who was not involved in writing up the 
consultation findings collate the response for this group. The collated responses for each 
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group were then assessed to check whether the key findings resonated or not with patient 
groups’ own experiences.  
Prior to sharing findings, we conducted a series of face-to-face consultations with the 
groups in July 2017. The consultations focused on experiences of diagnosis; for further 
details on the methods for these consultations see Brunton et al. (2017). Whilst we did not 
directly ask participants to comment on treatment issues, several participants did raise 
issues relating to treatment.   
Comments relating to Lyme disease treatment from both of these consultation exercises 
are reported in section 3.1.5.  
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Appendices 
Appendix 1: Example search strategy 
MEDLINE (via Ovid) search strategy 
1 exp Lyme Disease/ (9589) 
2 (lyme or lymes or lyme's).ti,ab. (9797) 
3 borreliosis.ti,ab. (3230) 
4 neuroborreliosis.ti,ab. (1024) 
5 (borrelia$ adj2 arthritis).ti,ab. (38) 
6 (erythema adj2 migrans).ti,ab. (1471) 
7 1 or 2 or 3 or 4 or 5 or 6 (12593) 
8 exp Borrelia burgdorferi Group/ (6501) 
9 (borrelia adj (burgdorferi or afzelii or garinii)).ti,ab. (7347) 
10 (b adj (burgdorferi or afzelii or garinii)).ti,ab. (4289) 
11 8 or 9 or 10 (8983) 
12 7 or 11 (14245) 
13 exp animals/ not humans/ (4279323) 
14 12 not 13 (11450) 
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Appendix 2: Flow of literature through the review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records removed:  
N = 31,094 
Duplicates: N = 29,561 
Year and publication types: N = 1,533 
Criteria on which reports 
were excluded (full text) 
Exclusion 1 - Date: 
Published before 2002 
Exclusion 2 – Focus: Not 
Lyme, borrelia, borreliosis 
Exclusion 3 – Evidence: Not 
empirical evidence 
Exclusion 4 – Population: 
Not humans 
Exclusion 5 – Biological 
mechanisms/markers 
Exclusion 6 – Language: 
Not in English 
Exclusion 7 – Registrations 
of trials 
Exclusion 8 – Case Reports 
Total records 
N = 52,268 
Full reports included in descriptive map 
N = 1,098 
Excluded on abstract  
N = 13,621 
Exc 1: 84 
Exc 2: 2,462 
Exc 3: 4,289 
Exc 4: 4,216 
Exc 5: 2,504 
Duplicates: 66 
Total records screened 
N = 21,174 
 
Full reports retrieved and screened 
N = 7,553 
Treatment studies 
N=78 
 
 
Full reports not available:  
N = 29 
 
Excluded on full report  
N = 6,426 
Exclusion 1: 3,960 
Exclusion 2: 190 
Exclusion 3: 1,249 
Exclusion 4: 94 
Exclusion 5: 166 
Exclusion 6: 731 
Exclusion 7: 36 
 
 
Criteria on which reports 
were excluded (abstract) 
Exclusion 1 - Date: 
Published before 1980 
Exclusion 2 – Focus: Not 
Lyme, borrelia, borreliosis 
Exclusion 3 – Evidence: Not 
empirical evidence 
Exclusion 4 – Population: 
Not humans 
Exclusion 5 – Biological 
mechanism/markers 
Studies focusing predominantly on experiences of 
diagnosis but with some limited focus on treatment 
N = 2 patient studies 
N = 5 clinician studies  
Diagnosis studies 
N=310 
 
 
Studies focusing on 
experiences of 
treatment 
N = 0 
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